Life Sciences

Covid-19 has already spurred a range of ripple effects across the life sciences industry—from disruptions in the supply chain and manufacturing, to delayed clinical trials and the grounding of all field personnel. While some of this impact was felt immediately, several scenarios that could have significant financial consequences have yet to play out.

Covid-19 has revealed critical shortcomings in the health care supply chain. Shortages of personal protective equipment (PPE), ventilators, and other vital supplies have hindered the U.S. health care system‘s response to this crisis, and additional waves of shortages are likely in coming months. Read our take to learn three requirements for a more resilient, transparent supply chain in light of Covid-19.